Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
Merus (MRUS) Stock Price & Analysis
250 Followers
MRUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.81 - $61.61
Previous Close$53.24
Volume1.72M
Average Volume (3M)874.23K
Market Cap
$3.12B
Enterprise Value$2.78B
Total Cash (Recent Filing)$354.38M
Total Debt (Recent Filing)$12.16M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 05, 2024EPS Estimate
-$0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding58,687,551
10 Day Avg. Volume2,077,475
30 Day Avg. Volume874,230
Standard Deviation0.18
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)8.81
Price to Sales (P/S)349.54
Price to Cash Flow (P/CF)-21.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue63.31
Enterprise Value/Gross Profit63.31
Enterprise Value/Ebitda-40.05
Forecast
1Y Price Target
$75.56Price Target Upside41.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Merus News
Bulls Say, Bears Say
Bulls Say
Competitive AdvantagePeto demonstrated a confirmed 67% objective response rate (ORR), showing effectiveness in combination with pembrolizumab for treating 1L HNSCC.
Drug Efficacy And Market PotentialAnalyst reiterates Buy rating and increases the price target to $85, reflecting confidence in the drug's market penetration and development.
Financial OutlookIncrease in peak penetration estimates for peto’ in the market and a decrease in the weighted average cost of capital indicate a stronger financial outlook for the drug's success.
Bears Say
Drug EfficacyMCL-145 data needs to mature, with current response rates of 9.6% for monotherapy and 10.5% for the combination therapy.
Investor SentimentInvestor questions suggest there is uncertainty regarding the upcoming peto+pembro data in 1L HNSCC at ASCO.
Treatment OptionsCurrent standard therapies such as Keytruda, cetuximab, and nivolumab have demonstrated limited efficacy in first-line head and neck squamous cell carcinoma.
---
Ownership Overview
7.11% Insiders
11.55% Mutual Funds
61.29% Other Institutional Investors
20.05% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $19.80 and its highest was $61.61 in the past 12 months.
What is Merus NV’s market cap?
Currently, no data Available
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is Aug 05, 2024 which is in 64 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on May 08, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.806 by $0.216.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -$0.77.
How many shares outstanding does Merus NV have?
Merus NV has 58,687,550 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.806. Following the earnings report the stock price went down -4.183%.
Which hedge fund is a major shareholder of Merus NV?
Among the largest hedge funds holding Merus NV’s share is Deerfield Management Company, LP. It holds Merus NV’s shares valued at 119M.
---
Merus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$75.56 (41.92% Upside)
$75.56 (41.92% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 70.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 26.3%
Last 30 Days ▲ 26.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
145.11%
12-Months-Change
Fundamentals
Return on Equity
-52.79%
Trailing 12-Months
Asset Growth
47.14%
Trailing 12-Months
Company Description
Merus NV
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
---
MRUS Stock 12 Month Forecast
Average Price Target
$75.56
▲(41.92% Upside)
Technical Analysis
Best Analysts Covering MRUS
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+67.86%
reiterated a buy rating 5 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +67.86% per trade.
---